[go: up one dir, main page]

NO983636D0 - Fremgangsmåte for behandling av trekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid - Google Patents

Fremgangsmåte for behandling av trekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid

Info

Publication number
NO983636D0
NO983636D0 NO983636A NO983636A NO983636D0 NO 983636 D0 NO983636 D0 NO 983636D0 NO 983636 A NO983636 A NO 983636A NO 983636 A NO983636 A NO 983636A NO 983636 D0 NO983636 D0 NO 983636D0
Authority
NO
Norway
Prior art keywords
norcisapride
nervous system
central nervous
optically pure
disease
Prior art date
Application number
NO983636A
Other languages
English (en)
Other versions
NO983636L (no
NO317178B1 (no
Inventor
John R Mccullough
Thomas P Jerussi
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO983636D0 publication Critical patent/NO983636D0/no
Publication of NO983636L publication Critical patent/NO983636L/no
Publication of NO317178B1 publication Critical patent/NO317178B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19983636A 1996-07-19 1998-08-07 Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen NO317178B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PCT/US1997/011629 WO1998003173A1 (en) 1996-07-19 1997-07-02 Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (3)

Publication Number Publication Date
NO983636D0 true NO983636D0 (no) 1998-08-07
NO983636L NO983636L (no) 1998-10-19
NO317178B1 NO317178B1 (no) 2004-09-06

Family

ID=24749413

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19983636A NO317178B1 (no) 1996-07-19 1998-08-07 Anvendelse av (+) norcisaprid for fremstilling av medikamenter samt farmasoytisk preparat og enhetsdoseform omfattende forbindelsen
NO20041166A NO20041166L (no) 1996-07-19 2004-03-19 Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20041166A NO20041166L (no) 1996-07-19 2004-03-19 Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament

Country Status (25)

Country Link
US (3) US5739151A (no)
EP (1) EP0896539B1 (no)
JP (1) JP3097697B2 (no)
KR (4) KR100399808B1 (no)
CN (1) CN1215992A (no)
AT (1) ATE197762T1 (no)
AU (1) AU3592097A (no)
BG (1) BG63190B1 (no)
BR (1) BR9708287A (no)
CA (1) CA2245768C (no)
CZ (1) CZ293478B6 (no)
DE (1) DE69703617T2 (no)
DK (1) DK0896539T3 (no)
ES (1) ES2152687T3 (no)
GR (1) GR3035460T3 (no)
HU (1) HUP9904360A3 (no)
IL (1) IL125703A0 (no)
IS (1) IS4820A (no)
NO (2) NO317178B1 (no)
NZ (1) NZ331291A (no)
PL (1) PL189610B1 (no)
PT (1) PT896539E (no)
SK (1) SK282673B6 (no)
TR (1) TR199801816T2 (no)
WO (1) WO1998003173A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
JP2001501960A (ja) * 1996-10-15 2001-02-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ シサプリドの合成
AU757077B2 (en) 1997-07-11 2003-01-30 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-HT3 and 5-HT4 mediated disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
CZ20004736A3 (cs) 1998-06-15 2001-09-12 Sepracor, Inc. Farmaceutický prostředek
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
IL140118A0 (en) 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders
TR200400187T2 (tr) * 1998-08-21 2006-11-21 Novartis Ag Yeni oral formülasyon.
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
JP5200288B2 (ja) * 2004-01-07 2013-06-05 アルメテオン、インコーポレイテッド 胃腸疾患および中枢神経系疾患の治療のための立体異性体化合物と方法
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2006029520A1 (en) * 2004-09-14 2006-03-23 Mcgill University Stimulators of 5-ht4 receptors and uses thereof
KR101351454B1 (ko) * 2005-08-31 2014-01-14 아메데온, 인코포레이티드 위장 및 중추 신경계 장애의 치료에 유용한 입체이성질체 화합물의 합성 방법 및 중간 생성물
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
BR112012008961A2 (pt) 2009-10-16 2019-09-24 Epiomed Therapeutics Inc tratamento de êmese
ES2587304T3 (es) * 2011-02-25 2016-10-21 Yuhan Corporation Derivados de diaminopirimidina y procedimientos para la preparación de los mismos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
EP1170010A3 (en) * 1992-07-07 2004-05-19 Sepracor Inc. Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1994001112A1 (en) * 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
IL125703A0 (en) 1999-04-11
WO1998003173A1 (en) 1998-01-29
ATE197762T1 (de) 2000-12-15
KR100328731B1 (ko) 2002-10-19
KR100399808B1 (ko) 2003-09-29
HUP9904360A3 (en) 2001-07-30
KR100422492B1 (ko) 2004-03-11
TR199801816T2 (xx) 2000-10-23
BG63190B1 (bg) 2001-06-29
IS4820A (is) 1998-08-10
US6114356A (en) 2000-09-05
PT896539E (pt) 2001-05-31
KR100533237B1 (ko) 2005-12-05
EP0896539A1 (en) 1999-02-17
PL189610B1 (pl) 2005-08-31
DK0896539T3 (da) 2001-02-19
JPH11510828A (ja) 1999-09-21
SK282673B6 (sk) 2002-11-06
KR20040007505A (ko) 2004-01-24
PL335254A1 (en) 2000-04-10
NO983636L (no) 1998-10-19
NO20041166L (no) 2004-03-19
ES2152687T3 (es) 2001-02-01
EP0896539B1 (en) 2000-11-29
BR9708287A (pt) 2000-01-18
BG102757A (en) 1999-08-31
US5739151A (en) 1998-04-14
CN1215992A (zh) 1999-05-05
SK123998A3 (en) 1999-03-12
CA2245768A1 (en) 1998-01-29
DE69703617T2 (de) 2001-04-12
KR20000064524A (ko) 2000-11-06
AU3592097A (en) 1998-02-10
HUP9904360A2 (hu) 2000-05-28
DE69703617D1 (de) 2001-01-04
NZ331291A (en) 2000-06-23
CZ293478B6 (cs) 2004-05-12
GR3035460T3 (en) 2001-05-31
CA2245768C (en) 2003-09-30
NO317178B1 (no) 2004-09-06
US5877188A (en) 1999-03-02
CZ250898A3 (cs) 1999-04-14
JP3097697B2 (ja) 2000-10-10

Similar Documents

Publication Publication Date Title
NO983636D0 (no) Fremgangsmåte for behandling av trekninger og sykdomstilstander i sentralnervesystemet ved anvendelse av optisk rent (+) norcisaprid
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
NO973231L (no) Nye forbindelser
YU37696A (sh) Postupak optičkog prečišćavanja jedinjenja
NO973516D0 (no) Behandling av urininkontinens ved anvendelse av (S)-oksybutenin og (S)-desetyloksybutenin
DK1000029T3 (da) Norcisaprid nyttig med hensyn til 5-HT3- og 5-HT4- medierede lidelser
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DE69914935D1 (de) 8-azabicyclo[3.2.1]okt-2-en- und -oktanderivate
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
NO993275L (no) Fremgangsmåte ved terapeutisk administrering av anti-CD40L-forbindelser
MXPA02000330A (es) Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados.
BG105218A (en) The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease
EA199800866A1 (ru) Способ снятия боли
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
DK0656209T3 (da) Melatoninderivater til anvendelse ved behandling af desynkroniseringsforstyrrelser
NO943372L (no) Behandling av migrene
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
NO990450D0 (no) Behandling av sinnslidelser
DK1152760T3 (da) Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
DK0793665T3 (da) Heterocykliske forbindelser og deres fremstilling og anvendelse